Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Christy Cassarly, Renee' H. Martin, Marc Chimowitz, Edsel A. Peña, Viswanathan Ramakrishnan & Yuko Y. Palesch. (2017) Assessing Type I error and power of multistate Markov models for panel data—A simulation study. Communications in Statistics - Simulation and Computation 46:9, pages 7040-7061.
Read now
Read now
Mohammad Ashraf Chaudhary, Elamin H Elbasha, Ritesh N Kumar & Esther C Nathanson. (2011) Cost–effectiveness of raltegravir in HIV/AIDS. Expert Review of Pharmacoeconomics & Outcomes Research 11:6, pages 627-639.
Read now
Read now
Felicitas C. Kühne, Jeremy Chancellor, Patrick Mollon, Daniela E. Myers, Michael Louie & William G. Powderly. (2010) A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals. HIV Clinical Trials 11:2, pages 80-99.
Read now
Read now
Articles from other publishers (9)
Starley B. Shade, Elliot Marseille, Valerie Kirby, Deepalika Chakravarty, Wayne T. Steward, Kimberly K. Koester, Adan Cajina & Janet J. Myers. (2021) Health information technology interventions and engagement in HIV care and achievement of viral suppression in publicly funded settings in the US: A cost-effectiveness analysis. PLOS Medicine 18:4, pages e1003389.
Crossref
Crossref
Anita J. Brogan, Sandra E. Talbird, Ashley E. Davis, Elizabeth M. La & Princy N. Kumar. (2021) The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States. PharmacoEconomics 39:4, pages 421-432.
Crossref
Crossref
Ahmed M. Bayoumi, Paul G. Barnett, Vilija R. Joyce, Susan C. Griffin, Huiying Sun, Nick J. Bansback, Mark Holodniy, Gillian Sanders, Sheldon T. Brown, Tassos C. Kyriakides, Brian Angus, D. William Cameron, Aslam H. Anis, Mark Sculpher & Douglas K. Owens. (2013) Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease. JAIDS Journal of Acquired Immune Deficiency Syndromes 64:4, pages 382-391.
Crossref
Crossref
Josephine Mauskopf. (2013) A Methodological Review of Models Used to Estimate the Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV Infection. PharmacoEconomics 31:11, pages 1031-1050.
Crossref
Crossref
Joost van RosmalenMehlika ToyJames F. O’Mahony. (2013) A Mathematical Approach for Evaluating Markov Models in Continuous Time without Discrete-Event Simulation. Medical Decision Making 33:6, pages 767-779.
Crossref
Crossref
Josephine Mauskopf, Anita J. Brogan, Sandra E. Talbird & Silas Martin. (2012) Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS 26:3, pages 355-364.
Crossref
Crossref
Marianne Harris, Bohdan Nosyk, Richard Harrigan, Viviane Dias Lima, Calvin Cohen & Julio Montaner. (2012) Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future. AIDS Research and Treatment 2012, pages 1-8.
Crossref
Crossref
Kurt Lippuner, Richard F. Pollock, Jayne Smith-Palmer, Thomas Meury & William J. Valentine. (2011) A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland. Applied Health Economics and Health Policy 9:6, pages 403-417.
Crossref
Crossref
Risheng Cao, Yiqiao Hu, Yun Wang, Emily C. Gurley, Elaine J. Studer, Xuan Wang, Phillip B. Hylemon, William M. Pandak, Arun J. Sanyal, Luyong Zhang & Huiping Zhou. (2010) Prevention of HIV Protease Inhibitor-Induced Dysregulation of Hepatic Lipid Metabolism by Raltegravir via Endoplasmic Reticulum Stress Signaling Pathways. Journal of Pharmacology and Experimental Therapeutics 334:2, pages 530-539.
Crossref
Crossref